Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.

Zhang S, Wu K, Feng J, Wu Z, Deng Q, Guo C, Xia B, Zhang J, Huang H, Zhu L, Zhang K, Shen B, Chen X, Ma S.

Oncotarget. 2016 Oct 18;7(42):68768-68780. doi: 10.18632/oncotarget.11967.


Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.

Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S.

Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2.


Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.

Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.

PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.


Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.

Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.

Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.


Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.

Rundall BK, Denlinger CE, Jones DR.

Surgery. 2005 Aug;138(2):360-7.


Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

Kuo WY, Wu CY, Hwu L, Lee JS, Tsai CH, Lin KP, Wang HE, Chou TY, Tsai CM, Gelovani J, Liu RS.

Oncotarget. 2015 Apr 20;6(11):8663-75.


A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.

PLoS One. 2010 Sep 14;5(9):e12417. doi: 10.1371/journal.pone.0012417.


Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.

Chien CW, Yao JH, Chang SY, Lee PC, Lee TC.

Toxicol Appl Pharmacol. 2011 Nov 15;257(1):59-66. doi: 10.1016/j.taap.2011.08.018. Epub 2011 Aug 25.


Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.

Rundall BK, Denlinger CE, Jones DR.

Surgery. 2004 Aug;136(2):416-25.


Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.

Wei Y, Zhou F, Lin Z, Shi L, Huang A, Liu T, Yu D, Wu G.

Anticancer Drugs. 2018 Mar;29(3):262-270. doi: 10.1097/CAD.0000000000000597.


Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.

Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, Zhang R, Zhang S, Wu G.

Int J Oncol. 2014 Feb;44(2):451-8. doi: 10.3892/ijo.2013.2193. Epub 2013 Nov 28.


Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.

Feng X, Han H, Zou D, Zhou J, Zhou W.

Oncotarget. 2017 Jan 10;8(2):3364-3379. doi: 10.18632/oncotarget.13764.


Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.

Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A.

Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10.


Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.

Liang Y, Zeng J, Jelicks L, Ma S, Liu J, Mei J, Perez-Soler R, Zou Y.

Curr Cancer Drug Targets. 2017;17(2):169-176. doi: 10.2174/1568009616666160331124759.


Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.

El-Awady RA, Hersi F, Al-Tunaiji H, Saleh EM, Abdel-Wahab AH, Al Homssi A, Suhail M, El-Serafi A, Al-Tel T.

Cancer Biol Ther. 2015;16(7):1056-70. doi: 10.1080/15384047.2015.1046023.


Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.

Hanke NT, Garland LL, Baker AF.

J Cancer Res Clin Oncol. 2016 Mar;142(3):549-60. doi: 10.1007/s00432-015-2047-6. Epub 2015 Sep 18.


Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16.


Supplemental Content

Support Center